Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023.
Guerra M, Alouani E, Hueso T, Ouali K, Danu A, Hollebecque A, Bahleda R, Willekens C, Gazzah A, Baldini C, Postel-Vinay S, Micol JB, Massard C, De Botton S, Ribrag V, Michot JM. Guerra M, et al. Among authors: alouani e. Eur J Haematol. 2024 Sep 21. doi: 10.1111/ejh.14307. Online ahead of print. Eur J Haematol. 2024. PMID: 39305190
Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series.
Platt JR, Allotey J, Alouani E, Glasbey J, Intini R, Lonardi S, Mazzoli G, Militello AM, Modest DP, Palle J, Pietrantonio F, Riyad K, Samuel L, Schulze AV, Shiu KK, Taieb J, Tolan DJM, West NP, Westwood AC, Williams CJM, Seligmann JF. Platt JR, et al. Among authors: alouani e. ESMO Open. 2024 Sep;9(9):103698. doi: 10.1016/j.esmoop.2024.103698. Epub 2024 Sep 5. ESMO Open. 2024. PMID: 39241497 Free PMC article.
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.
Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M, Kim S, Coutzac C, Perkins G, Alouani E, Marmorino F, Pernot S, Sinicrope FA, Elez E, Parent P, Cremolini C, Pietrantonio F, Lonardi S, Gallois C, Taieb J. Ambrosini M, et al. Among authors: alouani e. Eur J Cancer. 2024 Oct;210:114290. doi: 10.1016/j.ejca.2024.114290. Epub 2024 Aug 22. Eur J Cancer. 2024. PMID: 39216175
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, André T, Cohen R, Hollebecque A, Turpin A, Pernot S, Masson T, Di Fiore F, Dutherge M, Mazard T, Hautefeuille V, Van Laethem JL, De la Fouchardière C, Perkins G, Ben-Abdelghani M, Sclafani F, Aparicio T, Kim S, Vernerey D, Taieb J, Guimbaud R, Tougeron D. Moreau M, et al. Among authors: alouani e. Eur J Cancer. 2024 May;202:114033. doi: 10.1016/j.ejca.2024.114033. Epub 2024 Mar 21. Eur J Cancer. 2024. PMID: 38537314 Free article. Clinical Trial.
Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma.
Raufi AG, Pellicciotta I, Palermo CF, Sastra SA, Chen A, Alouani E, Maurer HC, May M, Iuga A, Rabadan R, Olive KP, Manji GA. Raufi AG, et al. Among authors: alouani e. bioRxiv [Preprint]. 2023 Dec 25:2023.12.24.573257. doi: 10.1101/2023.12.24.573257. bioRxiv. 2023. PMID: 38234792 Free PMC article. Preprint.
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Flecchia C, Auclin E, Alouani E, Mercier M, Hollebecque A, Turpin A, Mazard T, Pernot S, Dutherage M, Cohen R, Borg C, Hautefeuille V, Sclafani F, Ben-Abdelghani M, Aparicio T, De La Fouchardière C, Herve C, Perkins G, Heinrich K, Kunzmann V, Gallois C, Guimbaud R, Tougeron D, Taieb J. Flecchia C, et al. Among authors: alouani e. Br J Cancer. 2024 Feb;130(3):442-449. doi: 10.1038/s41416-023-02524-3. Epub 2023 Dec 15. Br J Cancer. 2024. PMID: 38102227
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B, Jones JC, McWilliams RR, Tougeron D, Halfdanarson TR, Guimbaud R, Hubbard JM, Flecchia C, Shi Q, Alouani E, Sonbol MB, Ticku J, Jin Z, Taieb J, Sinicrope FA. Saberzadeh-Ardestani B, et al. Among authors: alouani e. Eur J Cancer. 2024 Jan;196:113433. doi: 10.1016/j.ejca.2023.113433. Epub 2023 Nov 10. Eur J Cancer. 2024. PMID: 37979306
Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.
Manji GA, Lee S, Del Portillo A, May M, Ana SS, Alouani E, Sender N, Negri T, Gautier K, Ge L, Fan W, Xie M, Sethi A, Schrope B, Tan AC, Park H, Oberstein PE, Shah MA, Raufi AG. Manji GA, et al. Among authors: alouani e. JAMA Oncol. 2023 Dec 1;9(12):1702-1707. doi: 10.1001/jamaoncol.2023.4423. JAMA Oncol. 2023. PMID: 37856106 Free PMC article. Clinical Trial.
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Alouani E, Laparra A, Perret A, Sakkal M, Messayke S, Danlos FX, Ouali K, Hollebecque A, Even C, Ammari S, Baldini C, Champiat S, Besse B, Robert C, Guettier C, Samuel D, Lambotte O, De Martin E, Michot JM. Alouani E, et al. Eur J Cancer. 2023 Nov;193:113313. doi: 10.1016/j.ejca.2023.113313. Epub 2023 Aug 26. Eur J Cancer. 2023. PMID: 37748398
20 results